- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03548675
Pharmacogenetics Informed Tricyclic Antidepressant Dosing (PITA) (PITA)
Pharmacogenetics to Improve Personalized Antidepressant Dosing in Patients With Severe Depression;a Randomized Controlled Trial Using Tricyclic Antidepressants
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Nijmegen, Netherlands, 6500 HB
- Radboudumc Dept of Psychiatry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients are in- and outpatients, having a primary diagnosis of severe major depressive disorder (SCID-I diagnosis in agreement with DSM-5 criteria and a Hamilton Rating Scale for Depression score ≥ 19 (HAM-D-17-item version), aged 18-65 years, who, according to their physician, are eligible for treatment with a TCA (Nortriptyline (NOR), Clomipramine (CLOMI) or Imipramine (IMI)). The choice of the specific TCA is at the discretion of the physician in attendance.
Exclusion Criteria:
- Psychotic depression
- Bipolar I or II disorder.
- Schizophrenia or other primary psychotic disorder.
- Drug or alcohol dependence in the past 3 months.
- Mental Retardation (IQ < 80).
- For women: pregnancy or possibility for pregnancy without adequate contraceptive measures.
- Breastfeeding.
- Serious medical illness affecting the CNS, including but not restricted to M Parkinson, SLE, brain tumour, CVA.
- Relevant medical illness as contra-indication for TCA use, such as recent myocardial infarction.
- Other drugs influencing the pharmacokinetics of the TCAs as based on a list of interacting drugs. In case of psychotropic co-medication only a benzodiazepine in a dose equivalent up to 4 mg lorazepam will be allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Genotype-guided TCA treatment
Genotype guided dosing of the TCAs in patients with a PM,IM,EM or UM phenotype based on pharmacogenetic test.
|
All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes.
Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
|
ACTIVE_COMPARATOR: Standard TCA treatment
Standard dosing of TCA in patients with a PM,IM, EM or UM phenotype based on pharmacogenetic test
|
All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes.
Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to TCA plasma concentration in the therapeutic range
Time Frame: During the 7 weeks treatment phase
|
Time to TCA plasma concentration in the therapeutic range
|
During the 7 weeks treatment phase
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of depressive symptoms
Time Frame: Difference between measurements at baseline and after 7 weeks of treatment
|
HAM-D reduction
|
Difference between measurements at baseline and after 7 weeks of treatment
|
Highest level of side effects
Time Frame: During the 7 weeks treatment phase
|
summary measure: FIBSER
|
During the 7 weeks treatment phase
|
Economic Evaluation (Cost Effectiveness)
Time Frame: 26 weeks after the start of treatment
|
Utility based on EQ5D5L measurement
|
26 weeks after the start of treatment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Joost Janzing, MD PhD, Radboudumc Dept of Psychiatry
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 848016004
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on TCA treatment
-
University Hospital, EssenCompletedAnal Intraepithelial Neoplasia (AIN) in HIV-infected PatientsGermany
-
Nova Scotia Health AuthorityRecruiting
-
Assiut UniversityNot yet recruiting
-
Allotex, Inc.WithdrawnHyperopiaAustria, Belgium, France, Ireland, Switzerland, United Kingdom
-
Henry Ford Health SystemCompletedPost-inflammatory HyperpigmentationUnited States
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
University Hospital TuebingenOcean Clinic Marbella, SpainCompletedBurn of Face, Head and/or Neck | PeelingSpain
-
Allotex, Inc.WithdrawnSafety and Efficacy of a Sub-epitheilal Transform™ Corneal Allograft (TCA) for Presbyopia CorrectionRefractive Errors | PresbyopiaAustria, Belgium, France, Ireland, Switzerland, United Kingdom
-
SUZAN OBAGIWithdrawn
-
Samueli Institute for Information BiologyU.S. Army Medical Research and Development Command; Defense Centers of Excellence...CompletedHeadache | Traumatic Brain InjuryUnited States